Jaan Biotherapeutics Awarded NIH Grant to Advance Viral Delivered MicroRNA Inhibitory Cardiac Muscle Regeneration Therapy
NEWS PROVIDED BY Jaan Biotherapeutics September 4th, 2020
Jaan Biotherapeutics ("JBT"), announced that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health under Award Number R43HL154884. Under the Phase I grant, JBT intends to advance its lead cardiac muscle regeneration viral delivered drug, JBT-miR2 through preclinical testing in large animals. The first indication of JBT-miR2 is for the treatment of Ischemic Heart Disease (IHD), the single largest cause of death of both men and women in the Western World.
JBT-miR2 is a first in class viral delivered microRNA inhibitor that reprograms cardiac muscle cells to divide within the damaged heart, and repair the heart muscle after permanent heart muscle injury, for example following a heart attack.
"The successful development of JBT-miR2, for the non-surgical treatment of cardiac muscle injury and this NIH grant further validates JBT’s expertise in the development of treatments for cardiovascular diseases by modulating the activity of specific microRNAs to regenerate what was previously thought of as unrepairable adult heart injured muscle,” said Dr. Brar, Co-Principal Investigator on the Phase I grant and Founder and Chief Executive Officer at JBT.
About JBT-miR2 and Ischemic Heart Disease: JBT has successfully demonstrated promising in vivo efficacy and safety of JBT-miR2 in murine models of IHD. IHD can be caused by an acute heart attack, which limits sufficient blood flow to the heart leading to irreversible death of cardiac muscle cells. Subsequent scar formation is commonly associated with progressive heart function deterioration along with a significantly increased probability of mortality. In the US alone there are approximately one million heart attacks a year that result in permanent heart muscle death. Despite timely coronary interventions in association with thrombolytic and antiplatelet therapy that restore arterial perfusion after a heart attack, many patients fail to recover full cardiac function because current treatments do not replace the lost heart muscle and prevent the transition to heart failure. JBT-miR2 could offer a new, adjunct treatment for IHD when administered shortly after a heart attack.
About Jaan Biotherapeutics: JBT is a cardiovascular biotherapeutic company focused on improving the lives of patients diagnosed with heart diseases by targeting microRNAs. JBT’s core competencies are in the discovery, design and development of microRNA modulating therapeutics, specifically for the treatment of cardiovascular diseases. The team at JBT has amassed decades of experience in numerous drug discovery programs that have successfully produced multiple clinical candidates. For more information, please visit www.JaanBio.com
Contact: Joseph Hansen, Chief Financial Officer and Investor Contact Jaan Biotherapeutics L.L.C. 6331 Nancy Ridge Dr., Suite 204 San Diego, CA 92121 www.jaanbio.com Cell 858-373-8473 or 858-869-3564 JWH000@gmail.com Info@JaanBio.com
SOURCE Jaan Biotherapeutics L.L.C.